Connect with us
GRANULES

Granules India Limited (GRANULES) Stock Analysis

Granules India Limited is an Indian pharmaceutical manufacturer focused on APIs, intermediates, and finished dosages. It supplies large-volume oral products and PFIs to global generics customers. The company operates multiple plants in India. It is listed on Indian stock exchanges.

Healthcare › Drug Manufacturers - Specialty & Generic
₹799.00
-0.03% 1W  |  +44.80% 52W
Market Cap
21.8k CR
P/E Ratio
28
52W High
₹923.6
52W Low
₹529.9
Div. Yield
0.22%
Beta
0.1
50 DMA
₹834.7
200 DMA
₹759
Profit Margin
12.1%
Inst. Own.
22.9%
Trendline Analysis
✅ BOUNCE FROM SUPPORT₹917.7₹871.5₹825.3₹779.2₹73320 May29 Jun04 Aug18 Sep16 Nov1.2Cr
Fundamentals
Profit & Loss
MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales1,1891,1561,1761,1809671,1381,1971,2101,2971,3881,4711,4771,560
YoY Sales growth+3%+1%-2%+20%-19%-2%+2%+3%+34%+22%+23%+22%+20%
Expenses9779059209217639079459631,0191,0801,1191,1381,222
Operating Profit213250256259203230252247278308352339338
OPM %18%22%22%22%21%20%21%20%21%22%24%23%22%
Other Income21223633-10-1-425211
Interest26292927262724242929332121
Depreciation53525353535764697274828084
Profit before tax136170176181128153198145176202262240243
Tax %25%26%26%26%24%23%23%22%26%26%23%25%25%
Net Profit10212613013597118152113131150202180182
EPS in Rs4.215.185.355.564.014.856.274.645.386.198.137.266.67
Growth — CAGR
Metric3Y5Y10Y
Revenue CAGR6.0%11.0%15.0%
Profit CAGR5.0%2.0%17.0%
Shareholding Pattern
Promoters37.39%
FIIs20.25%
DIIs15.33%
Public27.04%
GRANULES
Holdings Analysis
Key strengths & risk signals
63
Overall
49
Fundamental
78
Technical
Risks (3)
OVERVALUED! PEG of 5.83 means expensive relative to growth rate.
RECOVERY MODE! Current price (799.0) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.0% (1 week), 3.2% (1 month), 7.3% (3 months).
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (834.7) is above 200-day average (759.0) - positive signal.
GOOD YEAR! Stock gained 44.8% in the last year.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Fundamental & Technical Analysis
63Overall
49Fundamental
78Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 5.9% (MODERATE, 8/15). Profit CAGR: 4.8% (SLOW, 5/15).
Profit Margin
5/10
DECENT EFFICIENCY! 12.1% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 5.83 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.22% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.45 - strong balance sheet.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 29.95% public ownership - balanced ownership structure.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (834.7) is above 200-day average (759.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (799.0) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
10/10
GOOD YEAR! Stock gained 44.8% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 1,589,821 vs down days: 1,130,165. Ratio: 1.41x
RSI
3/5
NEUTRAL! RSI at 42.8 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 68.4% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.0% (1 week), 3.2% (1 month), 7.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
GRANULES
Concall / Investor Presentation
Earnings call transcripts & AI summaries
QuarterConcallSummary
Q1FY272026-10-06Concall PDF
Q4FY262026-07-27Concall PDF
Q2FY262026-01-28Concall PDF

Peer Comparison

Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
Industry peers
StockPriceP/EProfit MarginRevenue CAGR 5YProfit CAGR 5Y52W ChangeStock StrengthTrendlineYoY ProfitQoQ ProfitYoY RevenueQoQ Revenue
GRANULES₹799.002812.1%5.9%4.8%+44.8%63 BOUNCE FROM SUPPORT+39.2%+1.0%+18.8%+5.0%
APLLTD₹1,057.1024.610.0%9.5%25.4%+8.6%86 BREAKOUT–+93.6%–+21.1%
NEULANDLAB₹21,640.0061.419.6%18.5%30.6%+21.4%80 BREAKOUT-46.7%-65.1%-12.6%-29.9%
PPLPHARMA₹244.90–-2.1%7.6%–+25.1%60 CONSOLIDATING DOWN–-108.1%–+15.3%
WOCKPHARMA₹2,004.5079.510.7%7.8%–+48.2%60 APPROACHING RESISTANCE–-25.5%–+4.3%
AJANTPHARM₹3,360.6033.320.3%13.4%21.6%+31.2%79 APPROACHING SUPPORT–+16.1%–+10.3%
EMCURE₹2,338.8040.610.7%15.4%20.2%+69.4%87 BREAKOUT+33.7%+10.7%+24.3%+9.3%
IPCALAB₹1,865.5033.713.4%15.5%34.3%+28.6%83 BOUNCE FROM SUPPORT+32.7%-6.7%+13.8%+4.4%
Data from TradeAlone · Updated daily

GRANULES News